In the latest trading session, Novo Nordisk (NVO) closed at $80.57, marking a -0.57% move from the previous day.

2025年1月22日，制药公司诺和诺德（NVO）成交额为4.78亿美元，在当日美股中排第205名，成交额较昨日减少26.54%，当日成交量为590.44万。 诺和诺德（NVO）于2025年1月22日跌0.57%，报80.57美元，该股过去5个交易日跌2.83%，整个1月跌6.34%，年初至今跌6.34%，过去52周跌23.54%。

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

European stocks saw further gains on Wednesday, with Adidas (OTC:ADDYY)' robust holiday-quarter results driving German shares ...

Ameritas Advisory Services LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 453.3% during ...

(Reuters) - European stocks extended their recent run of gains on Wednesday, with strong holiday-quarter performance from ...

【诺和诺德盘前涨约3% 与Valo Health扩大合作 利用AI开发减肥药】丹麦制药巨头诺和诺德(NVO.US)盘前涨2.7%报88美元。消息上，公司和美国科技公司Valo Health日前表示，同意扩大2023年开发多达11种药物的合作协议范围，将利用人类数据和人工智能(AI)，以开发多达20种针对肥胖、二型糖尿病和心血管疾病的新疗法。

Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 10 years ago, it would be worth $3,537.42 today based on a ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

周二，美银证券对诺和诺德公司 (NOVOB:DC) (NYSE: NVO)表示持续信心，维持买入评级，目标价为1,075.00丹麦克朗。这一背书来自于围绕这家制药巨头未来业绩和竞争格局的各种行业讨论。

A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of ...